T. Rowe Price Investment Management
RARE icon

T. Rowe Price Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

T. Rowe Price Investment Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-402,521
Closed -$18.6M – 564
2022
Q4 		$18.6M Sell
402,521
-2,204,910
-85% -$86.7M 0.01% 465
2022
Q3 		$108M Buy
+2,607,431
New +$134M 0.09% 228

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

T. Rowe Price Investment Management's RARE Position: Q1 2023 in Review

T. Rowe Price Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2023, closing a stake of 402,521 shares — an estimated $18.6M sold.

T. Rowe Price Investment Management first reported a position in RARE in Q3 2022 and held it in 2 quarters. The position peaked at $108M in Q3 2022. 229 funds tracked by Wall St. Rank hold RARE as of Q1 2023.

  • T. Rowe Price Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 402,521 Ultragenyx Pharmaceutical shares in Q1 2023, an estimated $18.6M.
  • T. Rowe Price Investment Management first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Ultragenyx Pharmaceutical position peaked at $108M in Q3 2022.
  • 229 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2023, filed 15 May 2023.